Universe Pharmaceuticals Valuation
| UPC Stock | USD 0.27 0.15 35.71% |
Universe Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Universe Pharmaceuticals from inspecting the company fundamentals such as Operating Margin of (0.14) %, return on equity of -0.5, and Shares Outstanding of 8.66 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Universe Pharmaceuticals' valuation include:
Price Book 0.1352 | Enterprise Value | Enterprise Value Ebitda 0.3117 | Price Sales 0.0875 | Enterprise Value Revenue 0.0174 |
Overvalued
Today
Please note that Universe Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Universe Pharmaceuticals is based on 3 months time horizon. Increasing Universe Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Universe Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Universe Stock. However, Universe Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.27 | Real 0.26 | Hype 0.23 |
The real value of Universe Stock, also known as its intrinsic value, is the underlying worth of Universe Pharmaceuticals Company, which is reflected in its stock price. It is based on Universe Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Universe Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Universe Pharmaceuticals helps investors to forecast how Universe stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Universe Pharmaceuticals more accurately as focusing exclusively on Universe Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Universe Pharmaceuticals' intrinsic value based on its ongoing forecasts of Universe Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Universe Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Universe Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Universe Pharmaceuticals Cash |
|
Universe Valuation Trend
Comparing Universe Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Universe Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Universe Valuation Data Drivers
Universe Pharmaceuticals Total Value Analysis
Universe Pharmaceuticals is at this time projected to have company total value of (1.26 M) with market capitalization of 2.34 M, debt of 5.48 M, and cash on hands of 28.58 M. The negative valuation of Universe Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial commitments of the company both on and off balance sheet. Investors should carefully check all of the Universe Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.26 M) | 2.34 M | 5.48 M | 28.58 M |
Universe Pharmaceuticals Investor Information
About 37.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.14. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Universe Pharmaceuticals recorded a loss per share of 49.37. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 18th of November 2024. Based on the key indicators related to Universe Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Universe Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Universe Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Universe Pharmaceuticals has an asset utilization ratio of 60.63 percent. This indicates that the Company is making $0.61 for each dollar of assets. An increasing asset utilization means that Universe Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Universe Pharmaceuticals Ownership Allocation
30% of Universe Pharmaceuticals outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.Universe Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 32.31 M. Reported Net Loss for the year was (6.16 M) with profit before taxes, overhead, and interest of 7.56 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Universe Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Universe Pharmaceuticals and how it compares across the competition.
About Universe Pharmaceuticals Valuation
The stock valuation mechanism determines Universe Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Universe Pharmaceuticals. We calculate exposure to Universe Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Universe Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 11.9 M | 18 M | |
| Pretax Profit Margin | (0.14) | (0.13) | |
| Operating Profit Margin | (0.13) | (0.12) | |
| Net Loss | (0.22) | (0.21) | |
| Gross Profit Margin | 0.37 | 0.50 |
Universe Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 3.6 M | |
| Quarterly Earnings Growth Y O Y | -0.82 |
Universe Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Universe Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Universe we look at many different elements of the entity such as Universe's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Universe Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Universe Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Universe Pharmaceuticals' worth.Complementary Tools for Universe Stock analysis
When running Universe Pharmaceuticals' price analysis, check to measure Universe Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Universe Pharmaceuticals is operating at the current time. Most of Universe Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Universe Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Universe Pharmaceuticals' price. Additionally, you may evaluate how the addition of Universe Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |